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Abstract
Epithelial Mesenchymal Transition (EMT) is a crucial mechanism for carcinoma progression, as it provides routes for in situ
carcinoma cells to dissociate and become motile, leading to localized invasion and metastatic spread. Targeting EMT
therefore represents an important therapeutic strategy for cancer treatment. The discovery of oncogene addiction in
sustaining tumor growth has led to the rapid development of targeted therapeutics. Whilst initially optimized as anti-
proliferative agents, it is likely that some of these compounds may inhibit EMT initiation or sustenance, since EMT is also
modulated by similar signaling pathways that these compounds were designed to target. We have developed a novel
screening assay that can lead to the identification of compounds that can inhibit EMT initiated by growth factor signaling.
This assay is designed as a high-content screening assay where both cell growth and cell migration can be analyzed
simultaneously via time-course imaging in multi-well plates. Using this assay, we have validated several compounds as
viable EMT inhibitors. In particular, we have identified compounds targeting ALK5, MEK, and SRC as potent inhibitors that
can interfere with EGF, HGF, and IGF-1 induced EMT signaling. Overall, this EMT screening method provides a foundation for
improving the therapeutic value of recently developed compounds in advanced stage carcinoma.
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Introduction
Epithelial Mesenchymal Transition (EMT) is a fundamental
process driving embryonic development, particularly during
gastrulation and in morphogenesis of the heart primordium, neural
crest and somites [1-3]. Cells engaged in the EMT program
undergo complex changes in cell architecture and behavior. In a
typical epithelial layer, epithelial cells develop adhesive structures
betweenadjacentcells,suchasadherensjunctions,desmosomes and
tight junctions, to establish robust intercellular adhesions. Epithelial
cells are apico-basal polarized, with the apical and basal surfaces
serving different functions. Mesenchymal cells, on the other hand,
do not have stable intercellular junctions and possess front-to-back
leading edge polarity. These characteristics also increase the
migratory capacity in mesenchymal cells, owing to the shift of
weaker cell-cell adhesion and stronger cell-matrix adhesion. Thus,
the EMT program describes a series of events during which
epithelial cells lose many of their epithelial characteristics and take
on properties that are typical of mesenchymal cells.
For more than a decade, EMT has been recognized as a
potential mechanism for the progression of carcinoma [4-5]. At
the onset of tumor progression, dysregulation of the cell cycle
machinery can result in proliferation of the normal epithelia to
give rise to an adenoma. The adenoma, with additional genetic
and epigenetic alterations, can later progress to a carcinoma in situ.
The carcinoma in situ is believed to engage the EMT program at
the micro-invasive stage [5-6], allowing individual carcinoma cells
to migrate and intravasate into lymph and blood vessels and
eventually disseminate and metastasize to distant organs.
Metastasis of the primary tumor is assisted by the release of
cytokines and growth factors that are secreted by the surrounding
stroma [7-9]. Cancer patients are reported to have elevated serum
levels of growth factors, namely hepatocyte growth factor (HGF),
epidermal growth factor (EGF), transforming growth factor-beta
(TGF-b) and insulin-like growth factor-1 (IGF-1), among others. In
addition, numerous carcinoma are found to have over-expression
of either wild-type or mutated kinases [10-11]. These kinase
oncogenes play important roles in growth factor signal transduc-
tion regulation, and their dysregulation can lead to survival and
excessive proliferation of cancer cells as well as the initiation and
sustenance of the EMT program and tumor metastasis [12-14].
These findings have generated great interest in understanding the
role of oncogenes and their signaling cascades in tumor growth
and the EMT program.
The discovery of oncogene addiction in sustaining tumor
growth has led to the development of modern molecular targeted
therapeutics [15]. These small molecule inhibitors function by
binding to the ATP-binding site of the dysregulated kinase
oncogene, thereby inhibiting the phosphorylation and activation
of its signal transduction cascade responsible for sustaining tumor
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targeted small molecule inhibitors in killing cancer cells or
preventing tumor growth. Examples include Imatinib Mesylate
for the treatment of chronic myeloid leukemia [16], and Gefitinib
for the treatment of non-small-cell lung cancer [17]. Whilst
originally identified and optimized for their anti-proliferative
effects, evidence suggests that some of these targeted small
molecule inhibitors may also inhibit EMT initiation or sustenance,
since the EMT program is modulated by similar signaling
pathways for which these molecules have been generated [9,18].
For example, Ki26894, an ALK5 inhibitor, has recently been
shown to decrease the invasiveness and EMT of scirrhous gastric
cancer cells [19]. However, an extensive screening effort to
identify and quantify the relative effectiveness of existing targeted
small molecule inhibitors in EMT modulation has not been
methodically attempted.
In this paper, we present the design and development of a novel
EMT inhibition drug screening assay (spot migration assay) using a
model carcinoma reporter cell line (NBT-II), which can be
induced to undergo EMT initiated by different growth factors:
EGF, HGF, or IGF-1. This assay allows us to identify the EMT
modulating properties of targeted small molecule compounds by
inhibiting EMT signaling in response to growth factor treatment.
Materials and Methods
Preparation of compound stock plates
Test compounds were purchased from various vendors (Selleck
Chemicals, Sigma Aldrich, SYN|thesis MedChem, and Tocris
Bioscience). Compound stocks were assembled in 96-well V-
bottom plates (Greiner). For screening studies, test compounds at
both 0.25 mM and 1.0 mM concentrations in DMSO were
prepared, with each occupying a single well in columns 2–11 of the
stock plates. For dose response studies, test compounds were
prepared in duplicate wells and serially diluted in DMSO, starting
with a 1.0 mM concentration. Stock plates were stored at 220
oC
and thawed to room temperature before use.
Spot migration assay
Nara Bladder Tumor No. 2 (NBT-II) cells were purchased from
American Type Culture Collection (ATCC) and were stably
transfected with mcherry-fluorescent H2B. Cells were maintained
in DMEM supplemented with 10% fetal bovine serum (FBS,
HyClone Thermo Scientific), 1 mg/ml puromycin (Sigma) and
100 units/ml penicillin-streptomycin (16 pen-strep, Invitrogen).
Cells were grown to 80% confluency in tissue culture flasks prior to
plating. Cells were trypsinized and concentrated to a density of
5610
6 cell/ml in CO2-independent medium (Invitrogen) supple-
mented with 10% FBS. The cell suspension was then evenly
dispensed into the wells of 2 columns of a 96-well V-bottom plate.
Using a robotic liquid-handling station (Bravo, Agilent Technol-
ogies), 0.5 ml of cell suspension was transferred from the 2 columns
of the cell suspension-loaded plate and deposited into the center of
the wells of 2 columns of a blank 96-well polystyrene tissue-culture
treated clear bottom, black assay plate (Corning #3904). This
process was repeated six times so that all 96 wells of the assay plate
were deposited with a cell suspension spot. The plate was then
sealed to minimize evaporation of the cell suspension spots and
transferred to a 37
oC, 5% CO2 incubator to allow for cells to
attach to the culture surface. After 1 h, the plate was gently
washed with medium once to remove unattached cells, refreshed
with 100 ml of assay medium (DMEM supplemented with 10%
FBS and 16 pen-strep), and then further incubated to allow for
cell-cell contacts to establish in the cell colonies.
After 4 h of incubation, the cell colonies for each well were
imaged using a confocal microplate imager (MetaXpress Ultra,
Molecular Devices) with 106Plan Fluor objective, 561 nm laser
excitation and 593/40 nm emission filter configuration. Four tiled,
non-overlapping images were acquired around the center of each
well, and were then stitched together during image analysis to
generate a montage covering an area of 3.2 mm63.2 mm. These
images (T1) represent the initial state of the cell colonies before
EMT induction.
After the T1 images were acquired, 1 ml of test compounds were
transferred from compound stock plates and added to the assay
plates. Appropriate negative controls (1 ml DMSO) and positive
controls (1 ml 1.0 mM compound in DMSO) were also added into
columns 1 and 12 of each assay plate, respectively. The assay was
optimized to use AG1478, JNJ-38877605 and BMS-536924 as
reference positive control compounds for EGF-, HGF- and IGF-
1-induced EMT, respectively. The cultures were then further
incubated overnight.
The next day, 50 ml of growth factor-containing medium was
added to each well of the assay plates. For each of the growth
factor-induced EMT spot migration assays, we optimized the final
growth factor concentrations in each well to be 20 ng/ml EGF
(Sigma), 4 ng/ml HGF (Calbiochem) or 150 ng/ml IGF-1 (R&D
Systems), respectively. The cultures were then incubated for
another 24 h, to allow for EMT and sufficient cell motility/
dispersion to occur in the cell colonies.
Finally, the cell colonies were imaged again using the microplate
imager, as described above. These images (T2) represent the final
state of the cell colonies after compound treatment and EMT
induction. The acquired T1 and T2 image sets for each assay plate
were then sent for image analysis.
Image analysis routine
The acquisition of each well was obtained by four adjacent field
images with no interstice in between. Each field image was loaded
and nuclei were initially segmented independently of other fields to
prevent artifact at the field border. Nuclei segmentation was
achieved by combining a wavelet transform which is robust to
noise and inhomogeneous background, and a watershed algorithm
based on intensities to split nuclei clusters. Mask of nuclei
segmentation of the different fields were then stitched together
in order to obtain a large segmentation of the whole well. Cell
bodies were estimated by applying a morphological dilation on the
nucleus segmentation using a disk of 30 pixels (48 mm) in
diameter. In cells that were contiguous, such as in a cell colony,
nuclei segmentation dilation will result in the formation of
continuous region areas with surrounding cells which can then
be identified as colonies. In general, a well will contain one big
colony (corresponding to the initial cell spot) and several much
smaller colonies (corresponding to single cells, small cluster of cells,
dust and contamination). Only nuclei contained in the biggest
colony were kept and subsequently analyzed. A spreading
coefficient was derived from nuclei positions in order to measure
how much the colony had dispersed. The spreading coefficient is
defined as the standard deviation of the cell positions in the cell
colony relative to the center of the colony:
sp~
1
#Col
X
c[Col
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
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2z(cy{Coly)
2
q
where Col indicates all cells of a colony, #Col is the total cell
number, [Colx, Coly] is the average position of all nuclei in the
colony, [cx,c y] is the position of the cell c. The coefficient sp is
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dispersion from the colony center.
Total cell number and spreading coefficient values for each well
were then exported into an Excel sheet. The Cell Count Ratio
(CCR) and Cell Dispersion Ratio (CDR) values were calculated by
combining data calculated from T1 and T2 images for each well,
while the normalized CDR or CDR% of each well calculated by
taking the CDR values of negative and positive controls as the
boundary limits:
CCR~
#ColT2
#ColT1
;CDR~
spT2
spT1
;
CDR%~
CDR{CDRpos
CDRneg{CDRpos
|100%
where CDRpos and CDRneg are the average CDR values of the nega-
tive and positive control wells respectively in each test plate [20].
EMT time-lapse video
EMT inhibitory effects of selected compounds were validated by
NBT-II epithelial colony time-lapse videoscopy. NBT-II cells were
plated onto a 12-well plate (BD) at a low density of 2,000 cells per
well in 1 ml of assay medium. Cells were allowed to grow and
form epithelial colonies for a period of 72 h. The cultures were
then refreshed with assay medium containing test compounds and
further incubated overnight. The next day, growth factor (EGF,
HGF or IGF-1) was added prior to video imaging. Video imaging
of individual cell colonies was performed using a video microscope
incubator system (Axiovert-200M, Carl Zeiss). Time-lapse images
were taken at 5 min intervals for 19 h.
Western blots
NBT-II cells were treated with compounds at 0.5, 2 and 8 mM
overnight and incubated with a growth factor for 24 h. Cells were
lysed with protease/phosphatase inhibitor-containing RIPA buff-
er. Proteins were separated in 8% polyacrylamide gels and
transferred to PVDF membranes. Membranes were blocked in 5%
BSA and incubated at 4
oC overnight with MMP-13 (Millipore), E-
cadherin (BD) and a-tubulin (Sigma) primary antibodies. Mem-
branes were then developed with HRP-conjugated secondary
antibody (Amersham) and ECL substrate (Millipore).
Statistical analysis
Error bars in CDR dose response plots represent standard
deviation of replicate samples. CDR IC50 values were calculated
through sigmoidal curve fitting of CDR dose response plots using
GraphPad Prism software.
Results
EMT spot migration assay design and assembly
An overview of the EMT screening assay is illustrated in
Figure 1. Our primary motivation for this assay was to screen for
compounds that have the propensity to inhibit EMT in cells
induced by exogenous growth factor signaling (Figure 1A). To
achieve this, we designed a high-throughput method of forming
compact, consistent epithelial cell colonies in 96 wells. Using a
multi-channel liquid-handling machine, a 0.5 ml high density
suspension of cells was directly deposited into the center of wells of
96-well plate, in a highly consistent manner (Figure 1B). As the cell
suspension drop was initially deposited onto a dry surface, the cells
were confined within the drop, and will be kept confined until they
firmly attach. Thus, the drop area essentially determined the
boundary of the initial epithelial colony that will be formed in the
well. As the environmental conditions essential for effective cell
attachment were 37
oC and 5% CO2, the plate was sealed to
prevent the 0.5 ml drop from evaporating in the incubator. In
addition, CO2-independent medium was used instead of normal
culture media to compensate for the lack of circulating CO2 in the
sealed plate. This sealed environment can be maintained for more
than an hour for cell attachment to be completed, after which the
wells can be gently washed and refreshed with normal culture
media. Due to the initial compactness, the attached cells can
quickly establish cell-cell contacts and consistent epithelial colonies
will form hours after cell plating.
In this study, we used the NBT-II reporter cell line. The cells
were stably transfected with H2B-mcherry to label the nuclei, so
that the migration of these cells could be tracked through live-cell
fluorescent imaging. NBT-II is an ideal cell model for the study of
EMT because of its fast EMT phenotypic response to several
known EMT stimuli, such as EGF, HGF and IGF-1 [21-22]. As
evident in Figure 1C, a complete EMT cell motility response was
achieved within 24 h after the addition of an EMT stimulus. This
short response time is critical for our screening assay design, as the
EMT quantification may be masked by cell proliferation response
if the motility response is too slow.
For compound screening, we first optimized the spot migration
assay to identify compounds that could inhibit EMT induced by
EGF, HGF, or IGF-1 signaling. Appropriate compounds (AG1478,
JNJ-38877605and BMS-536924)wereselected asreferencepositive
controls for each EGF, HGF and IGF-1 EMT assay, respectively.
The screen was conceptualized as a high-content imaging assay,
whereby colony nuclei in each well were imaged and analyzed prior
to compound treatment (T1 images), and 24 h after EMT induction
(T2 images). The effect of the screening compounds in this assay
were grouped into three categories: (1) compounds that are
cytotoxic or growth inhibitory to cells; (2) compounds that can
inhibit EMT, and are not growth inhibitory to cells (our desired
compound property); and (3) compounds that are not EMT or
growth inhibitory. The cell colony examples shown in Figure 1D
highlighted these three different categories. The grouping of
compounds into these three categories was determined through
image analysis of the plate images.
Image analysis and assay robustness
The analysis routine developed for this screening assay is
illustrated in Figure 2. For each well image, total cell numbers in
the colony and a spreadingcoefficientvalue were measured through
the image segmentation routine. The spreading coefficient is
defined as the standard deviation of the cell positions in the colony
relative to the center of the colony. By combining time-course
images of T1 and T2, we obtained the derived measurements Cell
Count Ratio (CCR) and Cell Dispersion Ratio (CDR), which
correspond to the cell growth status and the cell migration/
scattering status of each cell colony, respectively. The results
generated from these two ratio parameters were used to determine
the EMT inhibitory properties of the test compounds. We also
analyzed the uniformity and robustness of the assay (positive and
negative control well CDR uniformity plots shown in Figure S1).
We validated that the CDR signal was robust in the screening assay,
where intra-plate Z-factor was consistently above 0.5 between
positive and negative control signals.
Identification of potential EMT inhibitors in targeted
compounds screen
We tested a collection of 267 targeted inhibitor compounds to
determine if any of them could inhibit EGF-, HGF- or IGF-1-induced
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33183Figure 1. EMT spot migration screening assay overview. (A) Schematic of the spot migration screening assay to identify EMT inhibitory
compounds. EMT can be initiated and maintained in epithelial cells via growth factor signaling. This assay measures the dispersion of cells in the
presence of a test compound and an EMT inducer (EGF, HGF or IGF-1). The prevention of cell dispersion directly correlates to the propensity of a test
compound to block an induced EMT signaling pathway. (B) Screening assay image acquisition workflow. Robot-assisted plating of H2B-mcherry
transfected NBT-II cells into the well centers of 96-well plates. The initial plate image acquired at T1 served as the baseline reference for calculating
the CCR and CDR values for each well. The cells were treated with test compounds overnight and further incubated for 24 h with a growth factor to
induce EMT. (C) Final plate image acquired at T2 depicted the dispersion response of cells 24 h after addition of the compounds and growth factor
treatment. In the example shown, columns 2–11 were treated with 80 different test compounds at 6.67 mM and EGF. Column-1 served as negative
controls treated with 0.67% DMSO and EGF, while column-12 served as positive controls treated with 6.67 mM AG1478 and EGF. (D) Magnified images
of selected wells acquired at T1 and T2. Wells C12, H03 and D02 are examples of cell colonies treated by compounds that inhibited EGF-initiated cell
dispersion and did not inhibit cell growth. Well C01 is a cell colony undergoing EGF-induced EMT without any dispersion inhibition. Well E09 is a cell
colony treated by a growth inhibitory or toxic compound.
doi:10.1371/journal.pone.0033183.g001
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EMT targeted inhibitors screen is listed in Table S1. For hit finding,
we were interested in identifying compounds that are not growth
inhibitory (CCR $ 1.5) and could inhibit cell dispersion (CDR% #
50%) with a wide concentration range more than 0.5 log differences.
We therefore tested compounds at two concentrations (6.67 mMa n d
1.67 mM) in the EMT screen. Based on the screening data generated
and the selection criteria that were set, we shortlisted 25 compounds
that may potentially inhibit EGF-, HGF- or IGF-1-induced EMT.
To determine the EMT inhibition potency of the 25 shortlisted
compounds, we retested the compounds at diluting concentrations
starting from 6.67 mM, using the same EMT spot migration assay
for EGF, HGF or IGF-1 signaling. CDR dose response plots were
generated for each compound/growth factor combination and the
CDR IC50 values corresponding to the EMT inhibition potency
were determined. We thus revealed compounds that were very
effective against EMT by specific growth factors only (Figure 4).
We also discovered compounds that were potent against EMT
with all three growth factors (Figure 5). A summary of the CDR
IC50 values for the 25 compounds is listed in Table 1. In general,
we were able to group these compounds by their primary signaling
molecules that they were designed to target. This grouping
strategy helped us to validate this assay, where a c-Met inhibitor
(e.g. PF-04217903) specifically inhibited HGF-induced EMT,
while an EGFR inhibitor (e.g. Gefitinib) only inhibited EGF-
induced EMT. We also identified four groups of compounds
targeting ALK5, MEK, PI3K and SRC that were inhibitory to
several EMT-inducing growth factors.
Secondary assays to validate EMT inhibitors
We selected one compound from each target group and
validated their EMT inhibitory response via time lapse video.
We confirmed from the videos that an EGFR, c-Met and IGF-1R
inhibitor could specifically inhibit EGF-, HGF- or IGF-1-induced
EMT, respectively, as expected (Video S1, S2, S3). We also
showed that ALK5, MEK, PI3K and SRC targeting compounds
were indeed inhibiting migration induced by all three growth
factors (Video S4, S5, S6, S7); this is interesting as these
compounds are not the immediate and direct antagonists of the
growth factors linked to EMT signaling.
We further investigated whether ALK5, MEK, PI3K and SRC
targeting compounds could modulate the expression of EMT
markers, such as E-cadherin and matrix metalloproteinase-13
(MMP-13) under EMT-activated conditions (Figure S2). With the
exception of PI3K inhibitor GDC-0941, the compounds in general
abrogated MMP-13 expression in growth factor-treated samples.
Figure 2. Image processing procedure to determine the cell count and dispersion values of a well. (A) Colony nuclei image of each well
was obtained by stitching four adjacent, non-overlapping fields together. The example here shows a primary cell colony surrounded by several cell
outliers. (B) Nuclei segmentation, which consists of a wavelet transform and watershed algorithm steps, was applied to identify all nuclei in the well.
(C) The nuclei segmentation mask was then dilated to generate merging region areas where distinct cell clusters could be isolated. In general, the
largest region (yellow), representing the cell colony of interest, and other smaller regions (other colors), representing outlier cell clusters, were
identified. (D) Nuclei within the colony of interest were kept for measurement. Cell count was determined by the total nuclei count within the colony.
Cell dispersion was determined by applying the spreading coefficient formula. The blue arrow represents a vector centered on the colony center with
distance equal to the spreading coefficient.
doi:10.1371/journal.pone.0033183.g002
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expression [23]. We also showed that PD0325901 and AZD0530
augmented E-cadherin expression in all three growth factor-
treated conditions, while A83-01 and GDC-0941 restored the E-
cadherin protein levels. These results suggest that selective
inhibition of ALK5, MEK and SRC could potentially block
EMT by restoring E-cadherin-mediated cell adhesion and
reducing the invasion promoting MMP-13 and motility. These
findings are consistent with previous reports showing that ALK5,
MEK and SRC play a role in cell motility and tumor progression,
while PI3K predominately regulates cell proliferation [24-26].
Discussion
We have developed an EMT inhibition screening assay adapted
for high-throughput/high-content screening of small molecule
compounds. We have programmed a robotic liquid handler to
deposit consistent, reproducible cell colonies as confined spots onto
Figure 3. Cell dispersion ratio (CDR) vs. cell count ratio (CCR) plots. The graphs illustrate the behavior of NBT-II cells treated with different
test compounds and growth factors in the spot migration assay. CDR threshold was set at 50% CDR between positive control CDR and negative
control CDR. CCR threshold was set at 1.5 growth rate. We assessed compounds that inhibit cell dispersion (i.e. less than CDR threshold) and do not
severely inhibit cell growth (i.e. more than CCR threshold). To further refine our hits, the test compounds were run at a low and high concentration
(1.67 and 6.67 mM, respectively). Hit compounds (crossed squares) were classified as test compounds that satisfy the CDR and CCR threshold criteria
at both concentrations.
doi:10.1371/journal.pone.0033183.g003
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method of confining cells to generate cell colonies within a few
hours has not been previously attempted (the common alternative
method is to allow sparsely attached cells to grow and form
colonies, and this typically takes more than 3 days).
For image analysis, we use the wavelet transform and watershed
segmentation methods [27-28] because the resultant nuclei
segmentation is fast and accurate, suitable for high-content
screening (Figure 2). We design the image acquisition and analysis
method to encompass all cells in the well (Figure 1), rather than
using representative snapshots of the well. This eliminates the issue
of sampling bias, a common problem for high-content image
analysis especially when cell distribution is not uniform. As this
method accounts for all cells in the well, and the cell population per
well is large (typically more than 1,000 cells), we expect that the
analysis describing cell dispersion is reliable. In addition, because
the entire cell population is analyzed, we are able to employ
ratiometric analysis (i.e. comparing T2 and T1 images) to describe
the growth of the cell colony (Cell Count Ratio) as well as to derive
the colony dispersion over time (Cell Dispersion Ratio). We show
that CDR values for the plate controls, which determine the upper
and lower CDR boundaries, are consistent and robust (Figure S1),
and this increases the confidence of the assay in hit determination.
The EMT spot migration assay has key advantages over
traditionally described cell migration quantification methods, such
as the Boyden chamber or the in vitro scratch techniques [29-30].
In general, these techniques are prone to sampling bias because,
for practicality reasons, only representative microscope views and
not the entire well image are chosen for analysis. Another key
strength of the spot migration assay is that we are able to
quantitate the cell proliferation and cell dispersion of each well
simultaneously (Figure 2). This is important because we can then
use this to select compounds that are predominately anti-
migratory or EMT inhibitory against those that are generally
toxic to cells (Figure 3), as cell toxicity will inherently hinder cell
motility. Previous attempts to screen for cell motility modulating
agents are mainly based on the in vitro scratch assay [30], which
involves creating a scratch in a confluent cell monolayer and
measuring the speed at which the cell layer grows or migrates to
close this ‘‘wound’’. Although the method has also been adapted
for high-throughput screening by using robotic-driven pins to
generate scratches on multi-well plates [31-32], it has failed to
quantitatively differentiate whether the impairment of wound
closure by the test agent is due to the inhibition of cell motility or
the inhibition of cell growth pressure at the scratch front.
Our original motivation for designing this assay is to question
whether targeted compounds previously selected and optimized to
kill oncogene-addicted cells, can also be used to effectively inhibit
EMT signaling. We have thus designed and validated a novel
screening assay that can address the relative propensity and
Figure 4. EMT inhibitory property of an EGFR inhibitor, Gefitinib. T2 plate image and CDR dose response profile of Gefitinib, against EGF- (A)
HGF- (B) and IGF-1- (C) induced EMT.
doi:10.1371/journal.pone.0033183.g004
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induced EMT signaling. Through the primary screen and
subsequent secondary assays, we have discovered that the
druggable targets ALK5, MEK, SRC and to some extent PI3K
may play a more significant role in EMT modulation and cancer
progression, as their associated targeted compounds are inhibitory
to several EMT-inducing growth factors (Table 1). The targeted
compound library we assembled represents only a small subset of
the targeted compounds that have been developed by universities
and the pharmaceutical industry, and does not encompass all the
druggable targets identified to date. Therefore, further extension
of this EMT spot migration assay to include other diverse targeted
compound libraries, such as the one assembled by Bamborough et
al. [33], may allow us to discover other potent EMT inhibitors and
EMT modulating targets.
However, the major limitation of this screening assay is that the
reporter cell line NBT-II is not responsive to all exogenous growth
factors that are known to induce EMT. For example, VEGF-A
and VEGF-B have been reported to induce EMT in pancreatic
and bladder cancer cells [34-35] but they do not induce a
significant cell dispersion response in NBT-II (data not shown). In
addition, although NBT-II serves as an efficient model to quantify
the EMT inhibitory potential of compounds, the heterogeneous
nature of carcinoma itself implies that not all the compounds that
we have shortlisted here may inhibit EMT effectively as single
agents in other cancer cell lines, where multiple EMT pathways
may be switched on at the same time [13]. Thus, the selected
compounds are currently being evaluated for their ability to revert
the mesenchymal-like phenotype of carcinoma cell panels in vitro
and in tumor xenograft models in immuno-compromised mice.
We are also currently exploring the synergism effects between
compound combinations [36] in inhibiting the EMT phenotype
(example in Table S2). The objectives are to design new
therapeutic modalities based on the EMT concept to interfere
with tumor progression and to suppress resistance to chemother-
apeutic agents [18,37].
Figure 5. EMT inhibitory property of an ALK5 inhibitor, A83-01. T2 plate image and CDR dose response profile of A83-01, against EGF- (A)
HGF- (B) and IGF-1- (C) induced EMT.
doi:10.1371/journal.pone.0033183.g005
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Figure S1 Spot migration assay robustness. Cell Disper-
sion Ratio of positive controls [6.67 mM AG1478 (A) 6.67 mM
JNJ-38877605 (B) and 6.67 mM BMS-536924 (C)] and negative
controls [0.67% DMSO] (A-C) for 3 experiment sets of triplicate
plates (i.e. 8 data points per control condition per plate) is shown
here for the spot migration assay against EGF (A) HGF (B) and
IGF-1 (C) induction, respectively.
(PDF)
Figure S2 Modulation of EMT markers, E-cadherin and
MMP-13, by EMT inhibitors under EGF- (A) HGF- (B)
and IGF-1- (C) induced EMT conditions. E-cadherin
expression levels decreased with growth factor addition compared
with DMSO control, indicating cells had undergone EMT.
However, the E-cadherin level was restored or augmented with
increasing compound concentrations, due to EMT inhibition
effected by these compounds. We observed two bands for E-
cadherin, a 120 kDa band corresponding to the molecular weight
of E-cadherin and a second band at 90 kDa that corresponded to a
degradation form. Conversely, addition of HGF and IGF-1
increased MMP-13 expression levels compared with DMSO
control. In general, this increase in MMP-13 expression could be
abrogated with the addition of the EMT inhibitors. Positive
control for each panel: 2 mM AG1478 (A) JNJ-38877605 (B) and
BMS-536924 (C). a-tubulin was used here as a loading control.
(PDF)
Table S1 EMT spot migration data for 267 compounds tested at
1.67 and 6.67 mM concentrations, under EGF-, HGF- or IGF-1-
induced EMT conditions. Data where CCR#1.5 are highlighted
magenta, indicating compound condition was growth inhibitory.
Data where CDR%#50% are highlighted green, indicating
compound condition was dispersion inhibitory.
(PDF)
Table S2 EMT inhibition combination index (CI) values of
ALK5 inhibitor A83-01 and c-Met inhibitor JNJ-38877605
combination against HGF-induced EMT. Cell dispersion ratio
dose response profiles of A83-01 and JNJ-38877605 at fixed
combinations ratios of 1:4, 1:2, 1:1 and 3:1 were generated using
the spot migration assay. To determine if the EMT inhibitory
effects obtained with different compound combinations were
synergistic, we calculated the inhibition effect CI values according
to the Chou-Talalay method using CalcuSyn software (Biosoft)
(where CI.1.1, antagonism; CI=0.9–1.1, additive effect;
CI=0.2–0.9, synergism; and CI,0.2 strong synergism). The
results indicated that the combination treatment acted synergis-
tically against HGF-induced EMT.
(PDF)
Video S1 Time lapse recording highlighting the EMT inhibitory
response of the EGFR inhibitor, Gefitinib, under various EMT-
inducing conditions. EGF only (A) HGF only (B) IGF-1 only (C)
Gefitinib+EGF (D) Gefitinib+HGF (E) and Gefitinib+IGF-1 (F).
(AVI)
Video S2 Time lapse recording highlighting the EMT inhibitory
response of the c-MET inhibitor, PF-04217903, under various
EMT-inducing conditions. EGF only (A) HGF only (B) IGF-1 only
(C) PF-04217903+EGF (D) PF-04217903+HGF (E) and PF-
04217903+IGF-1 (F).
(AVI)
Video S3 Time lapse recording highlighting the EMT inhibitory
response of the IGF-1R inhibitor, BMS-536924, under various
EMT-inducing conditions. EGF only (A) HGF only (B) IGF-1 only
(C) BMS-536924+EGF (D) BMS-536924+HGF (E) and BMS-
536924+IGF-1 (F).
(AVI)
Video S4 Time lapse recording highlighting the EMT inhibitory
response of the ALK5 inhibitor, A83-01, under various EMT-
inducing conditions. EGF only (A) HGF only (B) IGF-1 only (C)
A83-01+EGF (D) A83-01+HGF (E) and A83-01+IGF-1 (F).
(AVI)
Video S5 Time lapse recording highlighting the EMT inhibitory
response of the MEK inhibitor, PD0325901, under various EMT-
inducing conditions. EGF only (A) HGF only (B) IGF-1 only (C)
PD0325901+EGF (D) PD0325901+HGF (E) and PD0325901+
IGF-1 (F).
(AVI)
Video S6 Time lapse recording highlighting the EMT inhibitory
response of the PI3K inhibitor, GDC-0941, under various EMT-
inducing conditions. EGF only (A) HGF only (B) IGF-1 only (C) GDC-
0941+EGF (D) GDC-0941+HGF (E) and GDC-0941+IGF-1 (F).
(AVI)
Video S7 Time lapse recording highlighting the EMT inhibitory
response of the SRC inhibitor, AZD0530, under various EMT-
Table 1. Summary of EMT inhibitor CDR IC50 values against
EGF-, HGF- and IGF-1-induced EMT.
Cell Dispersion IC50 (nM)
Name Target EGF HGF IGF-1
Development
stage
a
JNJ-38877605 c-MET .5000 94 .5000 Phase 1
PF-04217903 c-MET .5000 55 .5000 Phase 1
AG1478 EGFR 330 .5000 .5000 Research
Erlotinib EGFR 950 .5000 .5000 FDA approved
Gefitinib EGFR 880 .5000 .5000 FDA approved
Lapatinib EGFR 620 .5000 .5000 FDA approved
PD153035 EGFR 550 .5000 .5000 Research
PD158780 EGFR 1200 .5000 .5000 Research
WHI-P154 EGFR 800 .5000 .5000 Research
BMS-536924 IGF-1R, IR .5000 2300 170 Research
A83-01 ALK5 69 130 120 Research
D4476 ALK5 1100 1400 1900 Research
LY-364947 ALK5 140 180 240 Research
SB-431542 ALK5 1600 940 820 Research
SD-208 ALK5 85 110 150 Research
AZD6244 MEK1/2 840 790 880 Phase 1-2
CI-1040 MEK1/2 1000 820 1200 Phase 2
PD0325901 MEK1/2 31 20 8.9 Phase 1-2
GDC-0941 PI3K 740 380 500 Phase 1
PI-103 PI3K 680 380 400 Research
PIK-90 PI3K 950 400 620 Research
ZSTK474 PI3K 850 410 660 Phase 1
API-2 PKB, AKT 1300 .5000 .5000 Phase 1
AZD0530 SRC, ABL 560 510 240 Phase 1-2
PP1 SRC 2300 2000 1200 Research
aClinical trials information: ClinicalTrials.gov
doi:10.1371/journal.pone.0033183.t001
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AZD0530+EGF (D) AZD0530+HGF (E) and AZD0530+IGF-1 (F).
(AVI)
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